

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

March 29, 2017

Brian B. Yoor SVP, Finance and Chief Financial Officer Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064

> Re: Abbott Laboratories Form 8-K filed January 25, 2017

> > File No. 001-02189

Dear Mr. Yoor:

We have limited our review of your filing to the issue we have addressed in our comment. In our comment, we ask you to provide us with information so we may better understand your disclosure.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments.

## Form 8-K filed January 25, 2017

## Exhibit 99.1

1. Please refer to the non-GAAP reconciliations of financial information from continuing operations on pages 14 and 15. For each reconciliation and for each line item (other than intangible amortization), provide us a schedule of the "specified items" showing the amount and description of each specified item.

Brian B. Yoor Abbott Laboratories March 29, 2017 Page 2

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at 202-551-3494 with any questions.

Division of Corporation Finance Office of Healthcare and Insurance